Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Springworks Therapeutics Inc
(NQ:
SWTX
)
31.00
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
31.00
Bid (Size)
30.60 (1)
Ask (Size)
31.70 (1)
Prev. Close
31.00
Today's Range
31.00 - 31.00
52wk Range
18.00 - 53.92
Shares Outstanding
49,127,913
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
August 28, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
August 21, 2024
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance.
Via
Investor's Business Daily
Performance
YTD
-15.07%
-15.07%
1 Month
-20.92%
-20.92%
3 Month
-21.60%
-21.60%
6 Month
-28.85%
-28.85%
1 Year
+28.26%
+28.26%
More News
Read More
SWTX Stock Earnings: SpringWorks Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 07, 2024
Via
InvestorPlace
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 07, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics: Q4 Earnings Insights
February 27, 2024
Via
Benzinga
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
July 29, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
July 23, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Completes Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
July 01, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces Data to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
May 23, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the BofA Securities 2024 Health Care Conference
May 08, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SWTX Stock Earnings: SpringWorks Therapeutics Meets EPS, Beats Revenue for Q1 2024
May 02, 2024
Via
InvestorPlace
SpringWorks Therapeutics Reports First Quarter 2024 Financial Results and Highlights Recent Business Updates
May 02, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces Abstracts Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Report First Quarter 2024 Financial Results Thursday, May 2, 2024
April 18, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
March 13, 2024
Via
InvestorPlace
SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN
March 04, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
February 29, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Updates
February 27, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
February 22, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
January 31, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
December 21, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
SpringWorks Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
December 08, 2023
From
SpringWorks Therapeutics, Inc.
Via
GlobeNewswire
Why SpringWorks Therapeutics Stock (SWTX) Is Nosediving
December 05, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.